Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types

NCT03132792 is registered in ClinicalTrials.gov with Adaptimmune as lead sponsor.

NCT NCT03132792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03132792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Lead sponsor
Adaptimmune
Phase
Phase 1
Overall status
Completed
Start date
May 8, 2017
Completion date
November 19, 2025
Enrollment
39 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

afp expressing tumors, hepatocellular cancer